{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:15:44Z","timestamp":1791814544141,"version":"4.3.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-98402-4","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T05:47:06Z","timestamp":1745214426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of one-year outcomes between aflibercept and brolucizumab for treatment-na\u00efve pachychoroid neovasculopathy"],"prefix":"10.1038","volume":"15","author":[{"given":"Areum","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frenky Ramiro","family":"de Jesus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Chul","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Sagong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"98402_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000000331","volume":"35","author":"CE Pang","year":"2015","unstructured":"Pang, C. E. & Freund, K. B. Pachychoroid neovasculopathy. Retina 35, 1\u20139 (2015).","journal-title":"Retina"},{"key":"98402_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s40942-022-00429-6","volume":"8","author":"M Farvardin","year":"2022","unstructured":"Farvardin, M. et al. Pachychoroid neovasculopathy can mimic wet type age-related macular degeneration. Int. J. Retina Vitreous. 8, 78 (2022).","journal-title":"Int. J. Retina Vitreous"},{"key":"98402_CR3","doi-asserted-by":"publisher","first-page":"18423","DOI":"10.1038\/s41598-020-75451-5","volume":"10","author":"Y Hosoda","year":"2020","unstructured":"Hosoda, Y. et al. Deep phenotype unsupervised machine learning revealed the significance of pachychoroid features in etiology and visual prognosis of age-related macular degeneration. Sci. Rep. 10, 18423 (2020).","journal-title":"Sci. Rep."},{"key":"98402_CR4","doi-asserted-by":"publisher","first-page":"7379","DOI":"10.1038\/s41598-023-33936-z","volume":"13","author":"A Kuranami","year":"2023","unstructured":"Kuranami, A., Maruko, R., Maruko, I., Hasegawa, T. & Iida, T. Pachychoroid neovasculopathy has clinical properties that differ from conventional neovascular age-related macular degeneration. Sci. Rep. 13, 7379 (2023).","journal-title":"Sci. Rep."},{"key":"98402_CR5","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1007\/s10792-020-01522-1","volume":"40","author":"F Sartini","year":"2020","unstructured":"Sartini, F., Figus, M., Casini, G., Nardi, M. & Posarelli, C. Pachychoroid neovasculopathy: A type-1 choroidal neovascularization belonging to the pachychoroid spectrum\u2014pathogenesis, imaging and available treatment options. Int. Ophthalmol. 40, 3577\u20133589 (2020).","journal-title":"Int. Ophthalmol."},{"key":"98402_CR6","doi-asserted-by":"publisher","first-page":"16274","DOI":"10.1038\/s41598-021-95904-9","volume":"11","author":"H Matsumoto","year":"2021","unstructured":"Matsumoto, H. et al. Chronic choriocapillaris ischemia in dilated vortex vein region in pachychoroid neovasculopathy. Sci. Rep. 11, 16274 (2021).","journal-title":"Sci. Rep."},{"key":"98402_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bjophthalmol-2017-310378","volume":"102","author":"C Hara","year":"2018","unstructured":"Hara, C. et al. Characteristics of patients with neovascular age-related macular degeneration who are non-responders to intravitreal Aflibercept. Br. J. Ophthalmol. 102, 1\u20136 (2018).","journal-title":"Br. J. Ophthalmol."},{"key":"98402_CR8","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41598-019-38504-y","volume":"9","author":"BJ Jung","year":"2019","unstructured":"Jung, B. J. et al. Intravitreal Aflibercept and Ranibizumab for pachychoroid neovasculopathy. Sci. Rep. 9, 2055 (2019).","journal-title":"Sci. Rep."},{"key":"98402_CR9","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1097\/IAE.0000000000003615","volume":"42","author":"A Jeong","year":"2022","unstructured":"Jeong, A., Kang, W. & Sagong, M. Multimodal imaging features and treatment responses of choroidal neovascularization secondary to central serous chorioretinopathy. Retina 42, 2326\u20132335 (2022).","journal-title":"Retina"},{"key":"98402_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1167\/tvst.12.12.17","volume":"12","author":"M Carosielli","year":"2023","unstructured":"Carosielli, M. et al. Intravitreal Brolucizumab for pachychoroid neovasculopathy associated with chronic central serous chorioretinopathy. Transl. Vis. Sci. Technol. 12, 17 (2023).","journal-title":"Transl. Vis. Sci. Technol."},{"key":"98402_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1097\/IAE.0000000000002583","volume":"40","author":"YC Chang","year":"2020","unstructured":"Chang, Y. C. & Cheng, C. K. Difference between pachychoroid and non-pachychoroid polypoidal choroidal vasculopathy and their response to anti-vascular endothelial growth factor therapy. Retina 40, 1403\u20131411 (2020).","journal-title":"Retina"},{"key":"98402_CR12","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s00417-020-04661-4","volume":"258","author":"Y Kitajima","year":"2020","unstructured":"Kitajima, Y. et al. One-year outcome of combination therapy with intravitreal anti-vascular endothelial growth factor and photodynamic therapy in patients with pachychoroid neovasculopathy. Graefes Arch. Clin. Exp. Ophthalmol. 258, 1279\u20131285 (2020).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"98402_CR13","doi-asserted-by":"publisher","first-page":"e0248760","DOI":"10.1371\/journal.pone.0248760","volume":"16","author":"A Miki","year":"2021","unstructured":"Miki, A. et al. Photodynamic therapy combined with anti-vascular endothelial growth factor therapy for pachychoroid neovasculopathy. PLoS One 16, e0248760 (2021).","journal-title":"PLoS One"},{"key":"98402_CR14","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1038\/s41433-021-01418-z","volume":"35","author":"T Hikichi","year":"2021","unstructured":"Hikichi, T., Kubo, N. & Yamauchi, M. One-year comparison of anti-vascular endothelial growth factor and half-dose photodynamic therapies for pachychoroid neovasculopathy. Eye  35, 3367\u20133375 (2021).","journal-title":"Eye"},{"key":"98402_CR15","doi-asserted-by":"publisher","first-page":"12052","DOI":"10.1038\/s41598-021-91589-2","volume":"11","author":"J Yoon","year":"2021","unstructured":"Yoon, J. et al. Long-term outcome of intravitreal anti-vascular endothelial growth factor treatment for pachychoroid neovasculopathy. Sci. Rep. 11, 12052 (2021).","journal-title":"Sci. Rep."},{"key":"98402_CR16","doi-asserted-by":"publisher","first-page":"e0212055","DOI":"10.1371\/journal.pone.0212055","volume":"14","author":"K Azuma","year":"2019","unstructured":"Azuma, K. et al. The association of choroidal structure and its response to anti-VEGF treatment with the short-time outcome in pachychoroid neovasculopathy. PLoS One 14, e0212055 (2019).","journal-title":"PLoS One"},{"key":"98402_CR17","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1038\/s41598-024-52315-w","volume":"14","author":"G Boscia","year":"2024","unstructured":"Boscia, G. et al. Choroidal remodeling following different anti-VEGF therapies in neovascular AMD. Sci. Rep. 14, 1941 (2024).","journal-title":"Sci. Rep."},{"key":"98402_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00417-023-06278-9","volume":"262","author":"AD Abdin","year":"2024","unstructured":"Abdin, A. D. et al. Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up). Graefes Arch. Clin. Exp. Ophthalmol. 262, 457\u2013468 (2024).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"98402_CR19","doi-asserted-by":"publisher","first-page":"5517","DOI":"10.3390\/jcm11195517","volume":"11","author":"P Viggiano","year":"2022","unstructured":"Viggiano, P. et al. Short-term morphofunctional changes in previously treated neovascular AMD eyes switched to Brolucizumab. J. Clin. Med. 11, 5517 (2022).","journal-title":"J. Clin. Med."},{"key":"98402_CR20","doi-asserted-by":"publisher","first-page":"3893","DOI":"10.1167\/iovs.14-14447","volume":"55","author":"S Sonoda","year":"2014","unstructured":"Sonoda, S. et al. Choroidal structure in normal eyes and after photodynamic therapy determined by binarization of optical coherence tomographic images. Investig. Ophthalmol. Vis. Sci. 55, 3893\u20133899. https:\/\/doi.org\/10.1167\/iovs.14-14447 (2014).","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98402-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98402-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98402-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T05:47:07Z","timestamp":1745214427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-98402-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["98402"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-98402-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"13 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Sagong reported being a consultant for and receiving grant support from Samsung Bioepis, Novartis, Bayer, Roche, Allergan\/Abbvie, Celltrion, Alteogen, Alcon and Curacle, and receiving lecture fee from Novartis, Bayer, Roche, and Allergan\/Abbvie.All other authors declare no competing interests. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13674"}}